15.66

0.63% -0.10

After Hours: 15.66

Keros Therapeutics Inc (KROS)

Overview News Price History Option Chain Financials Why KROS Down? Discussions Forecast

Keros Therapeutics Inc stock is traded at $15.66, with a volume of 245.55K. It is down -0.63% in the last 24 hours and up +14.22% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Previous Close:

$15.76

Open:

$15.71

24h Volume:

245.55K

Relative Volume:

0.54

Market Cap:

$636.04M

Revenue:

Net Income/Loss:

$-168.05M

P/E Ratio:

-3.0526

EPS:

-5.13

Net Cash Flow:

$-146.15M

1W Performance:

+0.45%

1M Performance:

+14.22%

6M Performance:

+33.16%

1Y Performance:

-72.23%

1-Day Range:

$15.51

$15.84

1-Week Range:

$15.23

$15.85

52-Week Range:

$9.12

$72.37

Keros Therapeutics Inc Stock (KROS) Company Profile

Name

Keros Therapeutics Inc

Sector

Healthcare (1152)

Industry

Biotechnology (648)

Phone

617-314-6297

Address

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Employee

148

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

KROS's Discussions on Twitter

Compare KROS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KROS Keros Therapeutics Inc	15.66	635.63M	0	-168.05M	-146.15M	-5.13
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-16-24	Reiterated	Oppenheimer	Outperform
Dec-13-24	Reiterated	H.C. Wainwright	Buy
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy
Jun-25-24	Initiated	Oppenheimer	Outperform
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jul-31-23	Initiated	Wedbush	Outperform
Jul-26-23	Initiated	BofA Securities	Buy
Feb-14-23	Initiated	Cowen	Outperform
Oct-18-22	Initiated	Truist	Buy
Jul-26-22	Initiated	BTIG Research	Buy
Dec-08-20	Reiterated	H.C. Wainwright	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
May-04-20	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
May-04-20	Initiated	SVB Leerink	Outperform

View All

Keros Therapeutics Inc Stock (KROS) Latest News

Sep 11, 2025

Parkman Healthcare Partners LLC Has $2.22 Million Stock Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat

Sep 11, 2025

Invesco Ltd. Purchases 20,650 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat

Sep 11, 2025

Sep 09, 2025

Aug Retail: Is Keros Therapeutics Inc. still a buy after recent gainsJuly 2025 Weekly Recap & AI Driven Price Predictions - Lancaster City Council

Sep 09, 2025

Can AC Immune SA weather a recessionForecast Cut & High Yield Stock Recommendations - Lancaster City Council

Sep 09, 2025